Estrella Immunopharma Warrant
ESLAW
13 hedge funds and large institutions have $2.75M invested in Estrella Immunopharma Warrant in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
30% more funds holding
Funds holding: 10 → 13 (+3)
4% more capital invested
Capital invested by funds: $2.65M → $2.75M (+$103K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$9.08K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.29K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.44K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$266 |
| 5 |
CS
Clear Street
New York
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$511 |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$155 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $2.02M | – | – | – |
|
|
RCM
2
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| $500K | – | – | – |
|
|
ASM
3
ATW SPAC Management
New York
| $49K | – | – | – |
|
|
EFI
4
EHP Funds Inc
Toronto,
Canada
| $44K | +$9.08K | +40,900 | +30% |
|
|
KPF
5
K2 Principal Fund
Toronto,
Ontario, Canada
| $36K | – | – | – |
|
|
CH
6
CVI Holdings
Wilmington,
Delaware
| $27K | -$155 | -700 | -0.8% |
|
7
D.E. Shaw & Co
New York
| $27K | – | – | – |
|
|
8
Hudson Bay Capital Management
Stamford,
Connecticut
| $23K | -$511 | -2,300 | -3% |
|
|
WA
9
Whitebox Advisors
Minneapolis,
Minnesota
| $11K | – | – | – |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $9K | +$6.29K | +28,335 | New |
|
|
SSA
11
Schonfeld Strategic Advisors
New York
| $5K | +$4.44K | +20,000 | New |
|
|
CS
12
Clear Street
New York
| – | +$22 | +100 | New |
|
|
13
UBS Group
Zurich,
Switzerland
| – | +$266 | +1,200 | +625% |
|
ESLAW Hedge Fund Activity: Q2 2022 in Review
13 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q2 2022, worth a combined $2.75M — up 3.9% from $2.65M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ESLAW positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was EHP Funds Inc, adding an estimated $9.08K. The largest seller was Hudson Bay Capital Management, cutting an estimated $511.
- 13 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q2 2022, up from 10 in Q1 2022.
- Funds reported $2.75M of Estrella Immunopharma Warrant stock for Q2 2022, up 3.9% quarter-over-quarter.
- 3 funds opened new Estrella Immunopharma Warrant positions in Q2 2022 and 0 closed out, a net change of +3 holders.
- The largest Estrella Immunopharma Warrant buyer in Q2 2022 was EHP Funds Inc, an estimated $9.08K added.
- The largest Estrella Immunopharma Warrant seller in Q2 2022 was Hudson Bay Capital Management, an estimated $511 sold.
Based on aggregated 13F filings for Q2 2022.